DOP2015000133A - Composiciones que comprenden vortioxetina y donepezilo - Google Patents

Composiciones que comprenden vortioxetina y donepezilo

Info

Publication number
DOP2015000133A
DOP2015000133A DO2015000133A DO2015000133A DOP2015000133A DO P2015000133 A DOP2015000133 A DO P2015000133A DO 2015000133 A DO2015000133 A DO 2015000133A DO 2015000133 A DO2015000133 A DO 2015000133A DO P2015000133 A DOP2015000133 A DO P2015000133A
Authority
DO
Dominican Republic
Prior art keywords
compositions
vortioxetina
donepezilo
vortioxetine
donepezil
Prior art date
Application number
DO2015000133A
Other languages
English (en)
Inventor
Connie Sanchez Morillo
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of DOP2015000133A publication Critical patent/DOP2015000133A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN VORTIOXETINA Y DONEPEZILO Y EL USO DE UNA COMPOSICIÓN DE ESTE TIPO PARA EL TRATAMIENTO DE DISFUNCIONES COGNITIVAS. fig. 1 c
DO2015000133A 2012-12-13 2015-06-03 Composiciones que comprenden vortioxetina y donepezilo DOP2015000133A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261736799P 2012-12-13 2012-12-13

Publications (1)

Publication Number Publication Date
DOP2015000133A true DOP2015000133A (es) 2015-11-30

Family

ID=49943326

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000133A DOP2015000133A (es) 2012-12-13 2015-06-03 Composiciones que comprenden vortioxetina y donepezilo

Country Status (44)

Country Link
US (1) US9211288B2 (es)
EP (1) EP2931276B1 (es)
JP (1) JP6257641B2 (es)
KR (1) KR102171152B1 (es)
CN (1) CN104853755B (es)
AP (1) AP2015008498A0 (es)
AR (2) AR093939A1 (es)
AU (1) AU2013357308B2 (es)
BR (1) BR112015013675B1 (es)
CA (1) CA2893468C (es)
CL (1) CL2015001615A1 (es)
CR (1) CR20150303A (es)
CY (1) CY1120098T1 (es)
DK (1) DK2931276T3 (es)
DO (1) DOP2015000133A (es)
EA (1) EA028300B1 (es)
EC (1) ECSP15023182A (es)
ES (1) ES2663680T3 (es)
GE (1) GEP201706739B (es)
GT (1) GT201500143A (es)
HK (1) HK1212601A1 (es)
HR (1) HRP20180333T1 (es)
HU (1) HUE036280T2 (es)
IL (1) IL239192B (es)
LT (1) LT2931276T (es)
MA (1) MA38253B1 (es)
ME (1) ME03029B (es)
MX (1) MX362886B (es)
MY (1) MY171802A (es)
NI (1) NI201500078A (es)
NO (1) NO2970700T3 (es)
NZ (1) NZ708595A (es)
PE (1) PE20151026A1 (es)
PH (1) PH12015501302B1 (es)
PL (1) PL2931276T3 (es)
PT (1) PT2931276T (es)
RS (1) RS56949B1 (es)
RU (1) RU2635528C2 (es)
SG (1) SG11201504483YA (es)
SI (1) SI2931276T1 (es)
TN (1) TN2015000235A1 (es)
UA (1) UA114016C2 (es)
WO (1) WO2014090929A1 (es)
ZA (1) ZA201504274B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN105315184B (zh) * 2015-06-26 2017-03-29 上海医药工业研究院 一种沃替西汀的制备方法及其中间体
BR112018000841A8 (pt) * 2015-07-17 2022-11-22 Pasteur Institut Agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélites
CN105534933A (zh) * 2016-01-19 2016-05-04 美吉斯制药(厦门)有限公司 一种沃替西汀口腔崩解片及其制备方法
WO2018002115A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
WO2018182639A1 (en) 2017-03-30 2018-10-04 Rundle Research, LLC Methods of treating depression
US10398691B2 (en) 2017-03-30 2019-09-03 Rundle Research, LLC Methods of treating depression

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268871A1 (en) 1986-10-31 1988-06-01 Sumitomo Pharmaceuticals Company, Limited Quinoline derivatives
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
AU632458B2 (en) 1987-05-04 1993-01-07 Bonnie Davis Compounds for the treatment of alzheimer's disease
EP0403713A1 (en) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Novel acetylcholinesterase inhibitors
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
TW200462B (es) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
IL126308A0 (en) 1996-04-12 1999-05-09 Hoechst Marion Roussel Inc Isatin derivatives as acetylcholinesterase inhibitors and analgesics
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
WO2003082820A1 (fr) 2002-03-29 2003-10-09 Eisai Co., Ltd. Derive de (1-indanone)-(1,2,3,6-tetrahydropyridine)
DE60324788D1 (de) * 2002-05-31 2009-01-02 Lundbeck & Co As H Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
JP2006512417A (ja) * 2002-12-24 2006-04-13 ニューロケム (インターナショナル) リミテッド β−アミロイド関連疾患の治療のための治療用製剤
MY149152A (en) * 2006-05-08 2013-07-15 Teikoku Seiyaku Kk Percutaneous absorption preparations of antimentia drugs
AU2007258553A1 (en) * 2006-06-09 2007-12-21 Wyeth Method for enhancing cognitive function
EP2439201B1 (en) 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
WO2009005519A1 (en) * 2007-06-29 2009-01-08 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
MA38253A1 (fr) 2017-02-28
HUE036280T2 (hu) 2018-06-28
NI201500078A (es) 2016-02-15
RU2015122256A (ru) 2017-01-16
ECSP15023182A (es) 2015-12-31
RU2635528C2 (ru) 2017-11-13
IL239192A0 (en) 2015-07-30
BR112015013675B1 (pt) 2022-04-26
TN2015000235A1 (en) 2016-10-03
AR093939A1 (es) 2015-07-01
PL2931276T3 (pl) 2018-06-29
MY171802A (en) 2019-10-30
EA028300B1 (ru) 2017-10-31
CN104853755A (zh) 2015-08-19
EP2931276B1 (en) 2018-02-21
ZA201504274B (en) 2016-11-30
CA2893468A1 (en) 2014-06-19
AP2015008498A0 (en) 2015-05-31
CA2893468C (en) 2021-01-12
HRP20180333T1 (hr) 2018-04-06
IL239192B (en) 2019-03-31
GT201500143A (es) 2016-01-22
JP2016502990A (ja) 2016-02-01
US9211288B2 (en) 2015-12-15
LT2931276T (lt) 2018-04-10
DK2931276T3 (en) 2018-03-26
SG11201504483YA (en) 2015-07-30
GEP201706739B (en) 2017-09-25
US20150297585A1 (en) 2015-10-22
ES2663680T3 (es) 2018-04-16
NO2970700T3 (es) 2018-05-26
HK1212601A1 (zh) 2016-06-17
EP2931276A1 (en) 2015-10-21
KR102171152B1 (ko) 2020-10-29
AR125920A2 (es) 2023-08-23
EA201590932A1 (ru) 2015-10-30
AU2013357308B2 (en) 2017-08-31
KR20150095681A (ko) 2015-08-21
AU2013357308A1 (en) 2015-06-18
PH12015501302A1 (en) 2016-02-01
CY1120098T1 (el) 2018-12-12
SI2931276T1 (en) 2018-05-31
PH12015501302B1 (en) 2016-02-01
UA114016C2 (xx) 2017-04-10
WO2014090929A1 (en) 2014-06-19
MA38253B1 (fr) 2017-10-31
CL2015001615A1 (es) 2015-08-07
CN104853755B (zh) 2017-08-22
MX2015007269A (es) 2015-08-12
BR112015013675A2 (pt) 2017-07-11
NZ708595A (en) 2019-06-28
PT2931276T (pt) 2018-03-19
PE20151026A1 (es) 2015-07-11
RS56949B1 (sr) 2018-05-31
ME03029B (me) 2018-10-20
MX362886B (es) 2019-02-22
CR20150303A (es) 2016-07-07
JP6257641B2 (ja) 2018-01-10

Similar Documents

Publication Publication Date Title
DOP2015000133A (es) Composiciones que comprenden vortioxetina y donepezilo
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
DK3529248T3 (da) Farmaceutiske sammensætninger
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
CL2015002897A1 (es) Inhibidores de bace1
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017002090A2 (pt) formulação de fator viii
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
BR112018004243A2 (pt) misturas biocidas
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
CY1123408T1 (el) Φαρμακευτικες συνθεσεις και χρηση των αυτων
CL2013001945A1 (es) Compuestos derivados de pirazol de fórmulas (ia) o (ib), antagonistas de crth2; composiciones farmaceuticas que los contienen; combinaciones farmaceuticas; su uso en la prevencion y/o el tratamiento de trastornos inflamatorios, infecciosos e inmunorreguladores.
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
DK3474902T3 (da) Farmaceutisk sammensætning der omfatter fluor-18-mærkede gasser
DK3153163T3 (da) Farmaceutisk forbindelse der omfatter 13 glycerider, formulering og anvendelse deraf